Chuck Royce's AKBA Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 28,373 shares of Akebia Therapeutics, Inc. (AKBA) worth $39,438, representing 0.00% of the portfolio. First purchased in 2017-Q3, this short-term holding has been held for 5 quarters.
Based on 13F filings, Chuck Royce has maintained this position in AKBA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 28,373 shares. Largest reduction occurred in Q2 2018, reducing 537 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Akebia Therapeutics (AKBA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Akebia Therapeutics (AKBA) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +28,373 | New Buy | 28,373 | $1.39 |
| Q2 2018 | -537 | Sold Out | 0 | $0.00 |
| Q1 2018 | +190 | Add 54.76% | 537 | $9.31 |
| Q4 2017 | +100 | Add 40.49% | 347 | $14.41 |
| Q3 2017 | +247 | New Buy | 247 | $20.24 |
Chuck Royce's Akebia Therapeutics Investment FAQs
Chuck Royce first purchased Akebia Therapeutics, Inc. (AKBA) in Q3 2017, acquiring 247 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Akebia Therapeutics, Inc. (AKBA) for 5 quarters since Q3 2017.
Chuck Royce's largest addition to Akebia Therapeutics, Inc. (AKBA) was in Q1 2026, adding 28,373 shares worth $39,438.
According to the latest 13F filing for Q1 2026, Chuck Royce's firm, Royce & Associates Lp, owns 28,373 shares of Akebia Therapeutics, Inc. (AKBA), valued at approximately $39,438.
As of the Q1 2026 filing, Akebia Therapeutics, Inc. (AKBA) represents approximately 0.00% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Akebia Therapeutics, Inc. (AKBA) was 28,373 shares, as reported at the end of Q1 2026.